ADX10059 Migraine Prevention Study
A Phase 2B, Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-ranging, Multicentre Study to Investigate the Efficacy, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 for the Prevention of Migraine
Sponsor: Addex Pharma S.A.
Terminated
Incidence of abnormalities of liver function tests is higher than expected in this population.
Other terminated trials from Addex Pharma S.A.
- Dyskinesia, Drug-Induced · Phase PHASE2/PHASE3 · Aug 2022
- Dyskinesia, Drug-Induced · Phase PHASE2/PHASE3 · Aug 2022
More terminations from Addex Pharma S.A.
A PHASE2 clinical study on Migraine, this trial is terminated or withdrawn. The trial is conducted by Addex Pharma S.A. and has accumulated 6 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Dec 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Addex Pharma S.A.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Berkshire, United Kingdom , Berlin, Germany , Bochum, Germany , Cardiff, United Kingdom , Dresden, Germany , Essen, Germany , Frankfurt, Germany , Freiburg im Breisgau, Germany , Göppingen, Germany , Görlitz, Germany and 18 more locations